David Gilligan is a Consultant Oncologist at Cambridge University Hospitals & Royal Papworth Hospitals, Cambridge, UK and an Associate Lecturer at the University of Cambridge. He trained in Oncology at the Christie Hospital, Manchester, Royal Marsden Hospital, and University College Hospitals, London.

His main clinical interests are in Thoracic Oncology and Upper Gastrointestinal Oncology. He is an enthusiastic participator in clinical trials and has a keen interest in patient engagement and patient information.

He has been a member of the NCRI Lung Cancer Studies Group. He currently sits on NHS England Lung Cancer Clinical Expert Group (CEG). He is Chair of Lung Cancer Group, Anglia Cancer Network, Senior Medical Editor to Macmillan Cancer Information and Specialist Advisor to CancerHelp UK, a Trustee and Chair of Grants Committee of the Roy Castle Lung Cancer Foundation, the major patient facing UK wide lung cancer charity.

Since May 2017 he has been a member of BTOG Steering Committee.

Specialist Clinical Interests

Lung Cancer, Mesothelioma, Thymic Tumours, Oesophago-gastric Cancers & Unknown Primary Tumours

Research Interests

Clinical Trials

Education and Training


Current membership(s) of professional, national and regional bodies and university posts

GMC Number 3122095
Fellow Royal College of Radiologists
Fellow Royal College of Physicians [Edinburgh]
Recognised Clinical Teacher University of Cambridge
Member International Association for Study of Lung Cancer (IASLC)
Member British Thoracic Oncology Group

Recent and Important Publications

G Farquhar M, Penfold C, Benson J, Lovick R, Mahadeva R, Howson S, Burkin J, Booth S, Gilligan D, Todd C, Ewing G. Six key topics informal carers of patients with breathlessness in advanced disease want to learn about and why: MRC phase I study to inform an educational intervention. PLos One  2017 May 5;12(5):e0177081. doi: 10.1371/journal.pone.0177081. eCollection 2017

Szlosarek PW, Steele JP, Nolan L, Gilligan D, Taylor P, Spicer J, Lind M, Mitra S, Shamash J, Phillips MM, Luong P, Payne S, Hillman P, Ellis S, Szyszko T, Dancey G, Butcher L, Beck S, Avril NE, Thomson J, Johnston A, Tomsa M, Lawrence C, Schmid P, Crook T, Wu BW, Bomalaski JS, Lemoine N, Sheaff MT, Rudd RM, Fennell D, Hackshaw A. Arginine Deprivation With Pegylated Arginine Deiminase in Patients With Argininosuccinate Synthetase 1-Deficient Malignant Pleural Mesothelioma: A Randomized Clinical Trial. JAMA Oncol. 2016 Sep 1. doi: 10.1001/jamaoncol.2016.3049.

Harris C, Meek D, Gilligan D, Williams L, Solli P, Rintoul RC. Assessment and optimisation of lung cancer patients for treatment with curative intent. Clin Oncol (R Coll Radiol). 2016 Aug 18. pii: S0936-6555(16)30233-3. doi: 10.1016/j.clon.2016.08.002.

Ewing G, Ngwenya N, Benson J, Gilligan D, Bailey S, Seymour J & Farquhar M. Sharing news of a lung cancer diagnosis with adult family members and friends: a qualitative study to inform a supportive intervention. Patient Education and Counselling (2015) Oct 9. pii: S0738-3991(15)30080-X. doi: 10.1016/j.pec.2015.09.013.
Tan CS, Gilligan, D & Pacey, S.Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer. Lancet Oncology (2015) Sep;16(9):e447-59. doi: 10.1016/S1470-2045(15)00246-6.

NSCLC Meta-analysis Collaborative Group. Preoperative chemotherapy for non-small cell lung cancer: a systematic review and meta-analysis of individual patient data. Lancet (2014)  doi10.1016/50140-6736(13)62159-5.

Gilligan D. Acute Oncology: A bona fide subspecialty or a distraction from the day job? Clinical Oncology (2014) 26: 128-9

Din OS, Harden SV, Hudson E, Mohammed N, Pemberton LS, Lester JF, Biswas D, Magee L, Tufail A, Sheikh G, Gilligan D & Hatton, MQ. Accelerated hypofractionated radiotherapy for non small cell lung cancer: results from 4 UK centres. Radiotherapy & Oncology (2013) 109: 8-12

Prewett S, Aslam S, Williams MV & Gilligan D. The Management of Lung Cancer: A Survey of UK Oncologists. Clinical Oncology, (2012), doi10.1016/j.clon.2012.03.005

Navani N, Nankivell M, Stephens RJ, Parmar MK, Gilligan D, Nicholson M, Greon HJ, van Meerbeeck JP. Inaccurate clinical nodal staging of non-small cell lung cancer: evidence from MRC LU22 multicentre randomised controlled trial  Thorax (2010) 65: 463

Lee SM, Rudd R, Woll P, Ottensmeier C, Gilligan D, Price A, Spiro S, Gower N, Jitlal M & Hackshaw A. Randomised double-blind placebo-controlled trial of thalidomide in combination with gemcitabine and carboplatin in advanced non-small cell lung cancer. Journal of Clinical Oncology (2009) 27: 5248-54

Gilligan D , Nicholson M, Smith I, Greon H, Dalesio O, Goldstraw P, Hatton M, Hopwood P, Manegold C, Schramel F, Smit H, van Meerbeeck H, Nankivell M, Parmar M, Pugh C and Stephens R. Preoperative chemotherapy in patients with resectable non-small cell lung cancer: Results of the MRC LU22/NVALT 2/EORTC 08012 multicentre randomised trial and update of sytematic review. Lancet (2007) 369: 1929-37